Matches in SemOpenAlex for { <https://semopenalex.org/work/W3196142179> ?p ?o ?g. }
- W3196142179 endingPage "S18" @default.
- W3196142179 startingPage "S17" @default.
- W3196142179 abstract "Objectives: Preclinical evidence suggests that PARP inhibition (PARPi), anti-PD-1 therapy, and anti-angiogenic therapies have interactions that may support synergistic antitumor activity in pts with PROC. This phase 2 study evaluated activity of combination therapy with the PARPi niraparib, the PD-1 inhibitor dostarlimab, and bev in pts with PROC. Methods: Eligible pts had high-grade, platinum-resistant (progressed ≤6 mo after completion of ≥4 cycles of platinum-based chemo), recurrent epithelial ovarian, fallopian tube, primary peritoneal cancer, or recurrent carcinosarcoma of the ovary (high-grade mixed histology permitted). Pts had 1–2 prior lines of anticancer therapy for OC, and no prior therapy with an anti-PD-1/-L1 or PARPi. Pts received a regimen of 500 mg dostarlimab Q3W x 4, then 1000 mg Q6W + 15 mg/kg bev Q3W + niraparib 300 mg or 200 mg (for weight <77 kg or platelet count <150,000/µL at screening) QD until discontinuation. The primary endpoint was investigator-assessed objective response rate (ORR) per RECIST v1.1. Secondary objectives were progression-free survival (PFS), safety, and disease control rate (DCR). A posthoc analysis by biomarker (BRCA mutation [BRCAm] status, homologous recombination repair mutation [HRRm], and combined positive score [CPS; a measure of intratumoral and immune infiltrate PD-L1 expression], prior lines of therapy, and prior bev use) was performed. Results: Conclusions: Conclusion: Triplet therapy with niraparib, dostarlimab, and bev is tolerable and demonstrated clinical activity in pts with PROC, most of which were BRCA or HRR wt. AEs were as expected. Clinical trial identification: NCT03574779. Funding: GlaxoSmithKline. Preclinical evidence suggests that PARP inhibition (PARPi), anti-PD-1 therapy, and anti-angiogenic therapies have interactions that may support synergistic antitumor activity in pts with PROC. This phase 2 study evaluated activity of combination therapy with the PARPi niraparib, the PD-1 inhibitor dostarlimab, and bev in pts with PROC. Eligible pts had high-grade, platinum-resistant (progressed ≤6 mo after completion of ≥4 cycles of platinum-based chemo), recurrent epithelial ovarian, fallopian tube, primary peritoneal cancer, or recurrent carcinosarcoma of the ovary (high-grade mixed histology permitted). Pts had 1–2 prior lines of anticancer therapy for OC, and no prior therapy with an anti-PD-1/-L1 or PARPi. Pts received a regimen of 500 mg dostarlimab Q3W x 4, then 1000 mg Q6W + 15 mg/kg bev Q3W + niraparib 300 mg or 200 mg (for weight <77 kg or platelet count <150,000/µL at screening) QD until discontinuation. The primary endpoint was investigator-assessed objective response rate (ORR) per RECIST v1.1. Secondary objectives were progression-free survival (PFS), safety, and disease control rate (DCR). A posthoc analysis by biomarker (BRCA mutation [BRCAm] status, homologous recombination repair mutation [HRRm], and combined positive score [CPS; a measure of intratumoral and immune infiltrate PD-L1 expression], prior lines of therapy, and prior bev use) was performed. Conclusion: Triplet therapy with niraparib, dostarlimab, and bev is tolerable and demonstrated clinical activity in pts with PROC, most of which were BRCA or HRR wt. AEs were as expected." @default.
- W3196142179 created "2021-08-30" @default.
- W3196142179 creator A5000378651 @default.
- W3196142179 creator A5002551693 @default.
- W3196142179 creator A5002623514 @default.
- W3196142179 creator A5002656220 @default.
- W3196142179 creator A5021257078 @default.
- W3196142179 creator A5028738999 @default.
- W3196142179 creator A5031348375 @default.
- W3196142179 creator A5034800723 @default.
- W3196142179 creator A5041031647 @default.
- W3196142179 creator A5043625183 @default.
- W3196142179 creator A5044252805 @default.
- W3196142179 creator A5053645352 @default.
- W3196142179 creator A5056026943 @default.
- W3196142179 creator A5058008586 @default.
- W3196142179 creator A5060086956 @default.
- W3196142179 creator A5060953135 @default.
- W3196142179 creator A5062837404 @default.
- W3196142179 creator A5074433373 @default.
- W3196142179 date "2021-08-01" @default.
- W3196142179 modified "2023-09-25" @default.
- W3196142179 title "An open-label phase II study of dostarlimab (TSR-042), bevacizumab (bev), and niraparib combination in patients (pts) with platinum-resistant ovarian cancer (PROC): cohort A of the OPAL trial" @default.
- W3196142179 doi "https://doi.org/10.1016/s0090-8258(21)00680-6" @default.
- W3196142179 hasPublicationYear "2021" @default.
- W3196142179 type Work @default.
- W3196142179 sameAs 3196142179 @default.
- W3196142179 citedByCount "13" @default.
- W3196142179 countsByYear W31961421792021 @default.
- W3196142179 countsByYear W31961421792022 @default.
- W3196142179 countsByYear W31961421792023 @default.
- W3196142179 crossrefType "journal-article" @default.
- W3196142179 hasAuthorship W3196142179A5000378651 @default.
- W3196142179 hasAuthorship W3196142179A5002551693 @default.
- W3196142179 hasAuthorship W3196142179A5002623514 @default.
- W3196142179 hasAuthorship W3196142179A5002656220 @default.
- W3196142179 hasAuthorship W3196142179A5021257078 @default.
- W3196142179 hasAuthorship W3196142179A5028738999 @default.
- W3196142179 hasAuthorship W3196142179A5031348375 @default.
- W3196142179 hasAuthorship W3196142179A5034800723 @default.
- W3196142179 hasAuthorship W3196142179A5041031647 @default.
- W3196142179 hasAuthorship W3196142179A5043625183 @default.
- W3196142179 hasAuthorship W3196142179A5044252805 @default.
- W3196142179 hasAuthorship W3196142179A5053645352 @default.
- W3196142179 hasAuthorship W3196142179A5056026943 @default.
- W3196142179 hasAuthorship W3196142179A5058008586 @default.
- W3196142179 hasAuthorship W3196142179A5060086956 @default.
- W3196142179 hasAuthorship W3196142179A5060953135 @default.
- W3196142179 hasAuthorship W3196142179A5062837404 @default.
- W3196142179 hasAuthorship W3196142179A5074433373 @default.
- W3196142179 hasConcept C104317684 @default.
- W3196142179 hasConcept C121608353 @default.
- W3196142179 hasConcept C126322002 @default.
- W3196142179 hasConcept C143998085 @default.
- W3196142179 hasConcept C182979987 @default.
- W3196142179 hasConcept C185592680 @default.
- W3196142179 hasConcept C203092338 @default.
- W3196142179 hasConcept C2776694085 @default.
- W3196142179 hasConcept C2777802072 @default.
- W3196142179 hasConcept C2779962180 @default.
- W3196142179 hasConcept C2780194787 @default.
- W3196142179 hasConcept C2780427987 @default.
- W3196142179 hasConcept C2781413609 @default.
- W3196142179 hasConcept C31760486 @default.
- W3196142179 hasConcept C535046627 @default.
- W3196142179 hasConcept C55493867 @default.
- W3196142179 hasConcept C71924100 @default.
- W3196142179 hasConcept C82381507 @default.
- W3196142179 hasConcept C90924648 @default.
- W3196142179 hasConceptScore W3196142179C104317684 @default.
- W3196142179 hasConceptScore W3196142179C121608353 @default.
- W3196142179 hasConceptScore W3196142179C126322002 @default.
- W3196142179 hasConceptScore W3196142179C143998085 @default.
- W3196142179 hasConceptScore W3196142179C182979987 @default.
- W3196142179 hasConceptScore W3196142179C185592680 @default.
- W3196142179 hasConceptScore W3196142179C203092338 @default.
- W3196142179 hasConceptScore W3196142179C2776694085 @default.
- W3196142179 hasConceptScore W3196142179C2777802072 @default.
- W3196142179 hasConceptScore W3196142179C2779962180 @default.
- W3196142179 hasConceptScore W3196142179C2780194787 @default.
- W3196142179 hasConceptScore W3196142179C2780427987 @default.
- W3196142179 hasConceptScore W3196142179C2781413609 @default.
- W3196142179 hasConceptScore W3196142179C31760486 @default.
- W3196142179 hasConceptScore W3196142179C535046627 @default.
- W3196142179 hasConceptScore W3196142179C55493867 @default.
- W3196142179 hasConceptScore W3196142179C71924100 @default.
- W3196142179 hasConceptScore W3196142179C82381507 @default.
- W3196142179 hasConceptScore W3196142179C90924648 @default.
- W3196142179 hasLocation W31961421791 @default.
- W3196142179 hasOpenAccess W3196142179 @default.
- W3196142179 hasPrimaryLocation W31961421791 @default.
- W3196142179 hasRelatedWork W2942893873 @default.
- W3196142179 hasRelatedWork W2993972932 @default.
- W3196142179 hasRelatedWork W2994977341 @default.
- W3196142179 hasRelatedWork W3040343436 @default.
- W3196142179 hasRelatedWork W3047344552 @default.
- W3196142179 hasRelatedWork W3090114554 @default.
- W3196142179 hasRelatedWork W3186780355 @default.